Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

OIG publishes compliance oversight guidance for health care governing boards

By Yvonne Puig (US) & Karen Davis (US) on April 21, 2015
Email this postTweet this postLike this postShare this post on LinkedIn

On April 20, 2015, the HHS Office of Inspector General (OIG) published guidance for health care governing boards, articulating general features of effective compliance oversight and highlighting specific practical approaches available to boards.

The guidance encourages organizations to draw functional boundaries in organizational documents between the compliance, legal, and internal audit functions, while also “setting an expectation of cooperation and collaboration” among those functions. In emphasizing the importance of maintaining compliance as a function separate and not subordinate to the legal department, the guidance echoes statements in OIG guidance to boards published in 2004 (which, together with separate guidance published in 2003, has been a key resource for health care boards for the past decade).

Additionally, the guidance stresses the importance of the governing board receiving regular compliance-related reports from a variety of key players within the organization. It cites the potential use of “dashboard” products at board meetings to summarize compliance-related metrics. Further, OIG notes that holding regular executive sessions that exclude senior management may foster more open communication from compliance, legal, and internal audit leadership, while avoiding mistrust that may arise when senior management is excluded on an ad hoc basis. Boards should also closely examine compliance systems and processes to confirm that employees feel comfortable raising compliance concerns without fear of retaliation.

The OIG encourages governing boards to use resources such as the OIG’s voluntary compliance program documents as baseline tools in evaluating the strength of the organization’s compliance program. While boards have an ongoing duty to identify and monitor potential risk areas, OIG’s guidance emphasizes staying attuned to industry trends and legal developments, noting, for example, the newly-available information now available to boards (and the public) under the Sunshine Rule.

OIG also cites “multiple incentives,” including the statutory obligation to report and return overpayments within 60 days of identification, to build compliance programs that “encourage self-identification of compliance failures and to voluntarily disclose such failures to the Government.” OIG’s guidance indicates that final regulations implementing the statute “should provide additional guidance and clarity as to what it means to ‘identify’ an overpayment.”

Finally, the guidance emphasizes compliance as “an enterprise-wide responsibility,” and not solely the domain of the compliance and legal functions. It notes that organizations can assess individual performance in achieving compliance outcomes, and withhold incentives or provide bonuses accordingly.

Photo of Yvonne Puig (US) Yvonne Puig (US)

US Head of Life Sciences and Healthcare Yvonne Puig has a substantial commercial litigation practice in both state and federal courts. She represents hospitals, HMOs, managed care organizations, medical schools and other institutional health care providers and educational services companies. A partner in…

US Head of Life Sciences and Healthcare Yvonne Puig has a substantial commercial litigation practice in both state and federal courts. She represents hospitals, HMOs, managed care organizations, medical schools and other institutional health care providers and educational services companies. A partner in Norton Rose Fulbright’s Austin office, Yvonne’s practice involves commercial and health care litigation, antitrust, regulatory and compliance advice, crisis management, staff privileges, exclusive contracting and administrative law.

Read more about Yvonne Puig (US)Email
Show more Show less
Photo of Karen Davis (US) Karen Davis (US)
Read more about Karen Davis (US)Email
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Health Law Pulse
  • Organization:
    Norton Rose Fulbright
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo